DelveInsight’s, “Netherton Syndrome- Pipeline Insight, 2024” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Netherton Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Netherton Syndrome Research. Learn more about our innovative pipeline today! @ Netherton Syndrome Pipeline Outlook
Key Takeaways from the Netherton Syndrome Pipeline Report
- June 2024:- Daiichi Sankyo- A Phase 1b/2, Double-Blind, Placebo-Controlled, Randomized, Parallel-Arm Study to Explore Safety, Pharmacokinetics, and Early Clinical Signal of Efficacy of DS-2325a in Patients With Netherton Syndrome. This study will explore the safety, pharmacokinetics (PK), and early clinical signal efficacy of DS-2325a in adult patients with NS.
- June 2024:- Boehringer Ingelheim- This study is open to people with a skin disease called Netherton syndrome (NS). People can join the study if they are 12 years and older. The purpose of this study is to find out whether a medicine called spesolimab helps people with NS.
- DelveInsight’s Netherton Syndrome pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Netherton Syndrome treatment.
- The leading Netherton Syndrome Companies such as TenNor Therapeutics, KBP Biosciences, Debiopharm, Destiny Pharmaa, and others.
- Promising Netherton Syndrome Therapies such as DS-2325a, QRX003, Spesolimab, and others.
Stay informed about the cutting-edge advancements in Netherton Syndrome Treatments. Download for updates and be a part of the revolution in genetic disorder care @ Netherton Syndrome Clinical Trials Assessment
Netherton Syndrome Emerging Drugs Profile
- QRX003: Quoin Pharmaceuticals
QRX003 is a topical lotion, formulated with a proprietary Invisicare® delivery technology, and contains a broad- spectrum serine protease inhibitor, whose mechanism of action is intended to perform the function of a specific protein, called LEKTI. The absence of LEKTI in Netherton patients leads to excessive skin shedding resulting in a highly porous and compromised skin barrier. QRX003 is designed to lead to a more normalized skin shedding process and the formation of a stronger and more effective skin barrier.
- SXR-1096: Sixera Pharma
SXR1096 is a first-in-class, potent and selective small molecule inhibitor of kallikreins 5, 7 and 14 (KLK5, 7 and 14). The compound is formulated in a proprietary skin cream formulation designed for daily use in patients with rare skin conditions. Due to the inborn lack of the protease inhibitor LEKTI, KLK 5, 7 and 14 are overactive in the outermost layer of the skin in patients with Netherton syndrome. These drug targets can best be reached by applying the pharmaceutical directly on the skin. The disease is manifest from birth and can be life threatening in newborns.
Learn more about Netherton Syndrome Drugs opportunities in our groundbreaking Netherton Syndrome Research and development projects @ Netherton Syndrome Unmet Needs
Netherton Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
Netherton Syndrome Products have been categorized under various Molecule types such as
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Discover the latest advancements in Netherton Syndrome Treatment by visiting our website. Stay informed about how we're transforming the future of genetic disorder @ Netherton Syndrome Market Drivers and Barriers, and Future Perspectives
Scope of the Netherton Syndrome Pipeline Report
- Coverage- Global
- Netherton Syndrome Companies- TenNor Therapeutics, KBP Biosciences, Debiopharm, Destiny Pharmaa, and others.
- Netherton Syndrome Therapies- DS-2325a, QRX003, Spesolimab, and others.
- Netherton Syndrome Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Netherton Syndrome Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Netherton Syndrome Pipeline on our website @ Netherton Syndrome Drugs and Companies
Table of Content
- Introduction
- Executive Summary
- Netherton Syndrome: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Netherton Syndrome – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Drug Name: Company Name
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II/III)
- QRX003: Quoin Pharmaceuticals
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- SXR-1096: Sixera Pharma
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug Name: Company Name
- Drug profiles in the detailed report…..
- Inactive Products
- Netherton Syndrome Key Companies
- Netherton Syndrome Key Products
- Netherton Syndrome- Unmet Needs
- Netherton Syndrome- Market Drivers and Barriers
- Netherton Syndrome- Future Perspectives and Conclusion
- Netherton Syndrome Analyst Views
- Netherton Syndrome Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/
